Quadrivalent LAIV (MEDI8662)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Quadrivalent LAIV (MEDI8662), covering 2012-01-13 to 2012-01-13. Get the full timeline:
Most recent: Clinical Trial Update: A Study to Evaluate the Immunogenicity of Quadrivalent LAIV (MEDI8662) in Adults 18 to 49 Years of Age [Phase 3]